Advertisement

Therapeutic role of monoclonal antibodies in Migraine: A new paradigm

      Migraine continues to be the 6th most disabling illness with extremely incapacitating neurological symptoms affecting approximately 39 millions of US population. Besides its chronic illness, migraine impacts a significant economic burden with billions spent each year on medical services. American employers lose more than $13 billion each year as a result of 113 million lost work days due to a migraine. Apart from its burden of a migraine attack itself, migraine increases the risk for other physical and psychiatric conditions [

      Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. [PMID: 27844455].

      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. [PMID: 27844455].

        • Zhang A.
        • Jiang T.
        • Luo Y.
        • Zheng Z.
        • Shi X.
        • Xiao Z.
        • Fang Y.
        Efficacy of intravenous propacetamol hydrochloride in the treatment of an acute attack of migraine.
        Eur J Intern Med. 2014 Sep 1; 25 ([PMID: 25002083]): 629-632
        • Goadsby P.J.
        • Edvinsson L.
        The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.
        Annals of Neurology. 1993 Jan; 33: 48-56
        • Russell F.A.
        • King R.
        • Smillie S.J.
        • Kodji X.
        • Brain S.D.
        Calcitonin gene-related peptide: physiology and pathophysiology.
        Physiol Rev. 2014 Oct; 94 ([25287861]): 1099-1142
        • Edvinsson L.
        CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
        Br J Clin Pharmacol. 2015 Aug 1; 80 ([25731075]): 193-199
        • Walter S.
        • Bigal M.E.
        TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine.
        Curr Pain Headache Rep. 2015 Mar 1; 19 ([25754596]): 6
        • Hou M.
        • Xing H.
        • Cai Y.
        • Li B.
        • Wang X.
        • Li P.
        • Hu X.
        • Chen J.
        The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.
        J Headache Pain. 2017 Dec; 18 ([PMID: 28389966]): 42
        • Pellesi L.
        • Guerzoni S.
        • Pini L.A.
        Spotlight on anti-CGRP monoclonal antibodies in migraine: The clinical evidence to date.
        Clinical Pharmacology in Drug Development. 2017 Nov 1; 6 ([PMID: 28409893]): 534-547
        • Giamberardino M.A.
        • Affaitati G.
        • Curto M.
        • Negro A.
        • Costantini R.
        • Martelletti P.
        Anti-CGRP monoclonal antibodies in migraine: current perspectives.
        Intern Emerg Med. 2016 Dec 1; 11 ([PMID: 27339365]): 1045-1057
        • Schürks M.
        • Rist P.M.
        • Bigal M.E.
        • Buring J.E.
        • Lipton R.B.
        • Kurth T.
        Migraine and cardiovascular disease: systematic review and meta-analysis.
        BMJ. 2009 Oct 27; 339 ([PMID: 19861375]): b3914